Cargando…
The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature
BACKGROUND: Colorectal cancer is the third most common and the fourth most lethal cancer in the world. In the majority of cases, patients are diagnosed at an advanced stage or even metastatic, thus explaining the high mortality. The standard treatment for patients with locally advanced non-metastati...
Autores principales: | Chauvin, Anaïs, Wang, Chang-Shu, Geha, Sameh, Garde-Granger, Perrine, Mathieu, Alex-Ane, Lacasse, Vincent, Boisvert, François-Michel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898006/ https://www.ncbi.nlm.nih.gov/pubmed/29681787 http://dx.doi.org/10.1186/s12014-018-9192-2 |
Ejemplares similares
-
Identification of proteomic markers for prediction of the response to 5-Fluorouracil based neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients
por: Wang, Jianan, et al.
Publicado: (2022) -
Predictive value of proteomic markers for advanced rectal cancer with neoadjuvant chemoradiotherapy
por: Wang, Hanyang, et al.
Publicado: (2022) -
External Validation of a Radiomics Model for the Prediction of Complete Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer
por: Bordron, Anaïs, et al.
Publicado: (2022) -
Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer
por: Klautke, G, et al.
Publicado: (2005) -
Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-Analysis
por: Liu, Guo-Chen, et al.
Publicado: (2016)